Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
BOLT.US
id: 1280

Bolt Biotherapeutics (BOLT) Drug Development Issues Case

The plaintiff has voluntarily dismissed the case, ending the lawsuit.
N.D. California
Court
3:24-cv-03985
Case number
02/05/2021
Class period Start
05/14/2024
Class period End
09/02/2024
Lead Plaintiff motion deadline

  • $BOLT stockholder filed a claim against Bolt Biotherapeutics for overstating its lead drug's potential, which risked leadership changes and job cuts.

  • Following Bolt's May 14, 2024 announcement, $BOLT fell by over 37%.

  • Bolt’s investors can join this case to be notified about potential recovery.

Case Details:

On May 14, 2024, Bolt announced in a press release that it will stop further development of its lead asset, trastuzumab imbotolimod (BDC-1001), and will reduce its workforce by approximately 50%.

After Bolt’s announcement, several analysts downgraded the stock due to concerns about BDC-3042 and BDC-4182's prospects and the departure of the CEO and CMO.

This news caused $BOLT to drop by over 37%.

Based on these events, a $BOLT stockholder filed a claim against Bolt Biotherapeutics and its leaders, accusing them of the following:

  • BDC-1001 was less effective than Bolt claimed and unlikely to succeed.

  • The company overstated the clinical and commercial prospects of Bolt’s product pipeline.

  • This increased the risk of leadership changes and major job cuts.

Considering all the representations, investors have reasons to suspect that Bolt Biotherapeutics overstated its lead drug's potential, risking leadership changes and job cuts.

Case Status
Voluntary Dismissed
Alleged Offence
Misleading Statements, 
Failure to Disclose, 
Omissions
Suspected Party
Directors, 
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
05/14/2024
Filing date
07/02/2024
Lead Plaintiff Deadline
09/02/2024
Judge
Jacqueline Scott Corley